Article

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy

2021-09-15

Abstract excerpt

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light into mechanisms of action, safety and efficacy of CP using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCT) have reported highly v...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cfbb2225-1cb6-5ae1-9f51-ee3466a97dc4
DOI: 10.1101/2021.09.07.21263194

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacyDOI 10.1101/2021.09.07.21263194Read

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read

A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19Semantic proximity Read

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trialSemantic proximity Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent PlasmaSemantic proximity Read

Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 StudySemantic proximity Read

Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 studySemantic proximity Read

Functional Antibodies in COVID-19 Convalescent PlasmaSemantic proximity Read

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal AntibodiesSemantic proximity Read

COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized TrialsSemantic proximity Read

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read

Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)Semantic proximity Read